"Keytruda continues to benefit patients and drive growth" (Merck (MSD)) - Aug 5, 2026 - Q2 2026 Results
Sales • Biliary Tract Cancer • Bladder Cancer • Breast Cancer • Cervical Cancer • Fallopian Tube Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Head and Neck Cancer • Hepatocellular Cancer • Hormone Receptor Positive Breast Cancer • Liver Cancer • Lung Non-Small Cell Squamous Cancer • Oncology • Triple Negative Breast Cancer • Urothelial Cancer
|